Fresenius Seamless
Care of Massachusetts

an ESRD Seamless Care Organization

Fresenius Seamless Care of Massachusetts, LLC

Certain dialysis facilities in Massachusetts have chosen to participate in Fresenius Seamless Care of Massachusetts, an ESRD Seamless Care Organization (ESCO) in the Medicare Comprehensive ESRD Care model. See below for a listing of ESCO dialysis facilities in Massachusetts.

We’re Working to Improve Your Care

The goal of an ESCO is for dialysis facilities, nephrologists, and other health care providers to communicate and work together closely, so they can deliver high-quality care that meets the patient’s individual needs and preferences. ESCOs may be rewarded for providing their patients with higher quality, more coordinated care.

You Can Still Choose Any
Dialysis Facility, Doctor or Hospital

An ESCO Patient's Medicare benefits do not change. An ESCO is not a Medicare Advantage plan, a Health Maintenance Organization (HMO) plan, or an insurance plan of any kind.

ESCO Patients still have the right to use any dialysis facility, provider or hospital that accepts Medicare, at any time. A doctor may continue to recommend that an ESCO Patient see particular doctors or providers for their specific health needs, but it is always the patient's choice about which provider they use or dialysis facility or hospital they visit.

Questions or Concerns?

If you have questions or concerns, you can:

  • E-mail us at, call us at 1-844-209-9093, or bring it up next time you are in your provider’s office.
  • You can also call 1-800-MEDICARE (1-800-633-4227) and tell the representative you are calling about ESCOs.
  • TTY users should call 1-877-486-2048.

ESCO Leadership Team and Participants

Primary Contact

Eric Maaske

Fresenius Health Partners

Clinical Leadership Contact

Terry Ketchersid, MD

Integrated Care Group,
Fresenius Medical Care North America

Andrew Aronson, MD FACEP

Fresenius Health Partners
Health Services

Scott Dickison

Integrated Care Group

Maria Radonova

Integrated Care Group,
Fresenius Health Partners


Participants Owner

Bio-Medical Applications of Massachusetts, Inc.

Bio-Medical Applications of New Hampshire, Inc.

Kidney Care and Transplant Services of New England, PC

  • Aleksandr Kurbanov
  • Anthony Poindexter
  • Arley Diaz
  • Brittany Chew
  • Daniel Landry
  • Eli McKenna Weiss
  • George Lipkowitz
  • Gregory Braden
  • Jacquline Medeiros
  • Jeffrey Mulhern
  • Jennifer Mol
  • Jiuming Ye
  • John Lohlun
  • Jyovani Joubert
  • Kenneth McPartland
  • Marat Abdullin
  • Michael Plager
  • Mohamed Kamel
  • Robert Madden
  • Shirley Whitaker

Nephrology Associates of Merrimack Valley PC

  • Ashish Mahajan
  • Douglas Mesler
  • Joseph Rossacci

New England Nephrology Associates

  • Derya Bora Hazar
  • Joshua Hundert
  • Siddharth Bhatt
  • Steven M. Spiegel

Renal And Transplant Associates Of New England

  • Ashish Verma
  • Balaji Athreya
  • Barbara Greco
  • Dennis Dicampli
  • George Fares
  • Hemant Magoo
  • Jonathan Slater
  • Krishnan Babu
  • Michael Germain
  • Shaji Daniel

Participants Non-Owner

iHope Network Inc

  • Adrianne Sturtevant
  • Amanda Patterson
  • Andrea Jacobsen
  • Dan Tarlin
  • Joseph Reardon
  • Kathleen Holahan
  • Leo Keating
  • Lila Reid
  • Lillian Pozadas
  • Lourdes Tangarone
  • Mark Clukey
  • Michelle Clarke
  • Rachel Ganz
  • Rachel Murray
  • Richard Gordon


Fresenius Medical Care Holdings, Inc.
Fresenius Seamless Care
PO Box 162970
Austin, TX 78716-2970

Joint Ventures

There are no joint ventures between Participants and there are also no joint ventures between Participants and the Company.
For more information about joint ventures,
call 844-209-9093.

Governing Body

Commonwealth Nephrology Associates, Bora Hazar, MD
Kidney Care and Transplant Services of New England, Jeffrey Mulhern
RTANE (aka Western NE Renal Transplant Assoc.), Michael Germain, MD
Fresenius Kidney Care, Jessie Truitt
Fresenius Health Partners, Eric Maaske
Independent Consumer Advocate, Stacey Senat

Quality Performance

Performance Year 2017 will be reported in winter 2018.

Financial Performance

Performance Year 2017 will be reported in winter 2018.